ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
A phase 1/2 trial of Pembrolizumab in melanoma, run by ENB Therapeutics, Inc, active and no longer recruiting.
Overview
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors is a phase 1/2 interventional study registered as NCT04205227 by ENB Therapeutics, Inc, with 137 participants planned, started 2020-02-18 and due to reach its primary completion in 2026-01-01. Interventions recorded: ENB003, Pembrolizumab. Conditions listed: Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase 1/2A Trial of ENB 003 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Phase
Phase 1/2
Sponsor
ENB Therapeutics, Inc
Registry
Enrolled
137